Merit Medical Systems Executive Acquires $125,000 in Common Stock Amid Valuation Shifts

Brian G. Lloyd, serving as the Chief Legal Officer and Secretary for Merit Medical Systems Inc. (NASDAQ:MMSI), has executed a significant purchase of company stock. On May 7, 2026, Mr. Lloyd acquired 2,000 shares of common stock at a price of $62.625 per share, representing a total investment of $125,250. This specific transaction was completed indirectly via a 401(k) plan.The timing of this insider activity occurs as the stock trades at approximately $60.97, which is positioned near its 52-week low of $59.74. According to fair value assessments provided by InvestingPro, Merit Medical Systems has been identified as being among stocks on a 'Most Undervalued' list, suggesting that current market pricing may sit below intrinsic value.Following this recent acquisition, Mr. Lloyd holds a direct ownership stake of 62,132 shares of Merit Medical Systems common stock. In addition to these shares, the disclosure outlines several tiers of non-qualified stock options held by the executive:Rights to purchase 16,722 shares at an exercise price of $37.71, with a 25% annual vesting schedule beginning February 26, 2021, and an expiration date of February 26, 2027.Rights to purchase 9,681 shares at an exercise price of $56.25, with a 25% annual vesting schedule starting March 19, 2022, and expiring March 19, 2028.Rights to purchase 8,094 shares at an exercise price of $65.03, with a 25% annual vesting schedule beginning February 28, 2023, and expiring February 28, 2029.Rights to purchase 13,576 shares at an exercise price of $70.58, with a 25% annual vesting schedule starting February 28, 2024, and expiring February 28, 2030.This insider buying follows a period of robust financial performance for the company. During the first quarter of 2026, Merit Medical Systems outperformed market expectations on both top and bottom lines. The firm reported earnings per share (EPS) of $0.86, surpassing the anticipated $0.83. Revenue for the quarter reached $381.9 million, exceeding the projected $377.81 million.BofA Securities corroborated these results, noting that the company's first-quarter revenue of $382 million beat consensus estimates by roughly $4 million and reflected a 3% organic growth rate. Furthermore, quarterly EPS was reported at $0.94, beating consensus by $0.11, supported by an operating margin of 19.7%, which exceeded Street expectations by 180 basis points.

MMSI

Key Points

Merit Medical Systems reported Q1 2026 revenue of $381.9 million and EPS of $0.86, both beating consensus estimates.
Chief Legal Officer Brian G. Lloyd purchased 2,000 shares via a 401(k) at $62.625 per share, totaling $125,250.
Analyst opinions are mixed, with price targets ranging from $80 (BofA Securities) to $96 (Piper Sandler).

Executive Insider Activity and Financial Performance Analysis

Merit Medical Systems Inc. (NASDAQ:MMSI) recently saw notable insider activity when Brian G. Lloyd, the company's Chief Legal Officer and Secretary, increased his position in the firm through a 401(k) plan. On May 7, 2026, Mr. Lloyd purchased 2,000 shares of common stock at $62.625 per share, an investment totaling $125,250.

This transaction takes place while the company's stock is trading near its recent floor; current shares are priced at $60.97, which sits just above the 52-week low of $59.74. Such activity is noteworthy as InvestingPro analysis categorizes the company within its 'Most Undervalued' list based on Fair Value assessments.

Key Market Observations

1. Strong Operational Momentum: The company demonstrated significant financial strength in Q1 2026, with revenue of $381.9 million and earnings per share of $0.86. This outperformed both internal forecasts and broader analyst expectations, showcasing resilience in the medical technology sector.

2. Executive Alignment: The acquisition of 2,000 shares by a top legal officer, combined with Mr. Lloyd's substantial existing holdings (62,132 direct shares) and various layers of stock options, suggests an ongoing personal financial interest in the company's long-term trajectory.

3. Sector Impact: Merit Medical’s ability to maintain a 19.7% operating margin and achieve 3% organic growth indicates stable demand within the healthcare and medical device markets, potentially influencing broader sector sentiment regarding high-margin medical technology providers.

Risks and Uncertainties

1. Valuation Discrepancies: While some models suggest the stock is undervalued, analyst sentiment remains divided. For instance, Needham lowered its price target from $101 to $90 despite strong results, indicating that even with growth, market valuations may face downward pressure.

2. Dilution Concerns: BofA Securities has maintained a Neutral rating and reduced its price target from $100 to $80, citing concerns regarding potential deal dilution. This highlights a risk for shareholders in the medical device sector where strategic expansions can impact equity value.

3. Market Volatility: With the stock trading near 52-week lows, there is inherent uncertainty regarding whether current price levels represent a bottom or if further downward movement is expected by institutional investors.

Analyst Perspectives

The investment community currently holds varying views on MMSI's future valuation. Piper Sandler maintains an Overweight rating with a $96 price target, following discussions with the company's executive leadership that pointed toward a positive growth outlook. Conversely, the aforementioned shifts by Needham and BofA Securities reflect a more cautious stance regarding price targets and potential dilution risks.

Risks

Potential deal dilution as noted by BofA Securities, which may impact shareholder value.
Downward revisions of price targets by major firms like Needham and BofA Securities despite strong earnings.
Stock trading near its 52-week low of $59.74, indicating recent downward price pressure.

Menu